![](/img/cover-not-exists.png)
PND3 COST-UTILITY ANALYSIS OF NATALIZUMAB AS FIRST LINE THERAPY FOR HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS FROM A BRAZILIAN PRIVATE PAYER PERSPECTIVE
Rosim, R., Rigolon, J., Fahham, L.Volume:
19
Journal:
Value in Health Regional Issues
DOI:
10.1016/j.vhri.2019.08.333
Date:
October, 2019
File:
PDF, 381 KB
2019